Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10819181 | 1.00 | TSHR (0.53) | TSHRCHRM2CA9CHRM1CA12 | |
| SCHEMBL14601506 | 0.89 | TSHR (0.56) | TSHRCHRM2CA9CHRM1CA12 | |
| SCHEMBL26442009 | 0.88 | TSHR (0.41) | TSHRCHRM2CA9CHRM1CA12 | |
| SCHEMBL13296956 | 0.85 | TSHR (0.53) | TSHRCHRM2CA9CHRM1CA12 | |
| SCHEMBL21339698 | 0.85 | TSHR (0.53) | TSHRCHRM2CA9CHRM1CA12 | |
| SCHEMBL18490894 | 0.85 | TSHR (0.53) | TSHRCHRM2CA9CHRM1CA12 | |
| SCHEMBL30184333 | 0.85 | TSHR (0.53) | TSHRCHRM2CA9CHRM1CA12 | |
| SCHEMBL2101466 | 0.85 | TSHR (0.53) | TSHRCHRM2CA9CHRM1CA12 | |
| SCHEMBL26442086 | 0.84 | TSHR (0.38) | TSHRCA9CA12CA1CA2 | |
| SCHEMBL14049458 | 0.81 | TSHR (0.53) | TSHRCHRM2CA9CHRM1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137021-A1 | Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents | Rubedo Life Sciences, Inc. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137021-A1 | Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents | AGER, SENP6, SENP3 | TSHR 2431/4885CHRM2 851/4885CA9 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.